Icahn Enterprises IEP Pharma — Accounts Receivable Net
Other segment segments
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNet.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Icahn Enterprises's pharma — accounts receivable net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Icahn Enterprises's pharma — accounts receivable net?
- Icahn Enterprises (IEP) reported pharma — accounts receivable net of $27M in Q1 2026.
- How has Icahn Enterprises's pharma — accounts receivable net changed year-over-year?
- Icahn Enterprises's pharma — accounts receivable net decreased by 30.8% year-over-year, from $39M to $27M.
- What is the long-term trend for Icahn Enterprises's pharma — accounts receivable net?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — accounts receivable net has grown at a 11.2% compound annual growth rate (CAGR), from $95M to $145M.
- What does pharma — accounts receivable net mean?
- Measures the amount of money owed to the Pharma segment by customers for goods or services delivered, net of any allowances for doubtful accounts. This metric provides insight into the segment's credit management and the efficiency of its revenue collection cycle. High levels relative to sales may indicate potential collection risks or changes in customer payment terms.